Apoptosis gene polymorphisms and risk of prostate cancer: A hospital-based study of German patients treated with brachytherapy

Meyer, Andreas; Coinac, Irina; Bogdanova, Natalia; Dubrowinskaja, Natalia; Turmanov, Nurzhan; Haubold, Sabine; Schürmann, Peter; Imkamp, Florian; Klot, Christoph von; Merseburger, Axel S.; Machtens, S.; Bremer, Michael; Hillemanns, Peter; Kuczyk, Markus A.; Karstens, Johann H.; Serth, Jürgen; Dörk, Thilo

doi:10.1016/j.urolonc.2010.09.011

Cited by 26 publications

(27 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the association of D302H with PCa risk has been inconclusive. Lubahn et al and Meyer et al reported that the D302H polymorphism may play a protective role against PCa (Lubahn et al, 2010;Meyer et al, 2013); whereas, in a North Indian population, the H variant allele was associated with increased PCa risk (George et al, 2010).…”

Section: Impact Of Caspase-8 (Casp8)mentioning

confidence: 98%

Impact of Caspase-8 (CASP8) -652 6N Del and D302H Polymorphisms on Prostate Cancer in Different Ethnic Groups

Zhang

Li²,

Liu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Impact Of Caspase-8 (Casp8)mentioning

confidence: 98%

Impact of Caspase-8 (CASP8) -652 6N Del and D302H Polymorphisms on Prostate Cancer in Different Ethnic Groups

Zhang

Li²,

Liu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Among the genes analyzed for association between genetic variants and prostate cancer risk or aggressiveness are XRCC1 and XRCC3 (X-ray repair cross-complementing proteins 1 and 3), ERCC1 and ERCC2 (Excision repair cross-complementing rodent repair deficiency, complementation group 1 and 2), LIG4 (Ligase IV), ATM (Ataxia telangiectasia mutated), XPD (Xeroderma pigmentosum group D), MDM2 (Human mouse double-minute 2 protein), CDKN1A, and CDKN1B (Cyclin-Dependent Kinase Inhibitors 1A, and 1B), CCND1 (Cyclin D1) as well as BCL2 (B-cell lymphoma 2) and TP53 (tumor protein p53) [89][90][91][92][93][94][95][96][97][98][99][100][101][102]. Genetic variants within most of these genes were found to be associated with PCa aggressiveness or response to therapy.…”

Section: Dna Repair Cell Cycle Control and Apoptosismentioning

confidence: 99%

Genetic Association Studies on Prostate Cancer

Nikolic¹,

Savić‐Pavićević²,

Brajušković³

2016

Prostate Cancer - Leading-Edge Diagnostic Procedures and Treatments

View full text Add to dashboard Cite

The modern research on molecular basis of prostate cancer (PCa) development includes studies aiming to identify potential genetic markers which could be used in diagnostics and/or monitoring of PCa. Genome-wide association studies (GWASs) have identified over 75 variants associated with PCa risk. One of the major PCarelated regions identified through GWASs is found to be a segment of 8q24. Other important PCa-susceptibility regions are 17q12, 17q24, 10q11, and 19q13. Candidategene based approach has also provided evidence of association between PCa risk and genetic variants located in functionally significant genes (both protein-coding and noncoding RNA genes) involved in normal prostatic cell growth, malignant transformation, or in the development of metastases. Nevertheless, the success of these studies is questionable, since numerous candidates for PCa-susceptibility variants were identified, but these results failed to replicate. The main aim of both types of genetic association studies on PCa is the identification of potential PCa genetic markers which could be used for constructing reliable algorithms for evaluating the risk for PCa development and/or PCa progression.

show abstract

“…To date, a few molecular epidemiological studies have investigated the association between the RASSF1A Ala133Ser polymorphism and the cancer risk including breast cancer (Schagdarsurengin et al, 2005;Gao et al, 2008;Bergqvist et al, 2010;Donninger et al, 2011), lung cancer (Kanzaki et al, 2006;Xiao et al 2012), colorectal cancer (Kanzaki et al, 2006), head and neck cancer (Kanzaki et al, 2006), esophageal cancer (Kanzaki et al, 2006;Zhou et al, 2013), renal cell carcinoma (Kawai et al, 2012), hepatocellular carcinoma (Bayram, 2012), gastric cancer (Zhou et al, 2013), prostate cancer (Meyer et al, 2013). However, no consistent conclusion has been drawn.…”

Section: Research Articlementioning

confidence: 99%

“…Thus, a total of 14 case-control studies including 4572 cases and 4320 controls were analyzed in this meta-analysis (Schagdarsurengin et al, 2005;Kanzaki et al, 2006;Gao et. al, 2008;Xiao et al 2009;Bergqvist et al, 2010;Donninger et al, 2011;Bayram, 2012;Kawai et al 2012;Meyer et al, 2013;Zhou et al, 2013). The characteristics of selected studies are summarized in Table 1.…”

Section: Characteristics Of Eligible Studiesmentioning

confidence: 99%

“…The sample size in these case-control studies varied considerably (range . All studies were case-control studies, including four breast cancer studies (Schagdarsurengin et al, 2005;Gao et al, 2008;Bergqvist et al, 2010;Donninger et al, 2011), two lung cancer studies (Kanzaki et al, 2006;Xiao et al 2009), two esophageal squamous cell carcinoma (ESCC) studies (Kanzaki et al, 2006;Zhou et al, 2013), and the others including colorectal cancer (Kanzaki et al, 2006), head and neck cancer (Kanzaki et al, 2006), renal cell carcinoma (Kawai et al 2012), hepatocellular carcinoma (Bayram, 2012), gastric cancer (Zhou et al, 2013), prostate cancer (Meyer et al, 2013). 8 studies conducted in the Asian population, 5 in Caucasian population, and 1 in mixed population.…”

Section: Characteristics Of Eligible Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Association between RASSF1A Ala133Ser Polymorphism and Cancer Susceptibility: A Meta-Analysis Involving 8,892 Subjects

Bayram

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Published studies on the association between the Ras Association Domain Family 1 isoform A (RASSF1A) Ala133Ser polymorphism and cancer susceptibility have yielded conflicting results. Thus, a metaanalysis was here performed to assess the possible association. Materials and Methods: All eligible case-control studies published up to November 2013 on the association between RASSF1A Ala133Ser polymorphism and cancer susceptibility were identified by searching PubMed, Web of Science, Science Direct and hand search. Bothfixedeffect and random-effect models were used to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs) by using the Comprehensive Meta-Analysis software version 2.2. Results: A total of 10 studies including 4,572 cancer cases and 4,320 controls were included in the meta-analysis. Overall, significantly increased cancer risk was associated with the variant Ser133 when all studies were pooled (Ser vs Ala: OR=1.51, 95% CI=1.08-2.12, P heterogeneity ≤0.001; Ser/Ser+Ala/Ser vs Ala/Ala: OR=1.55, 95% CI=1.08-2.22, P heterogeneity ≤0.001). Moreover, in subgroup analyses by cancer types, a significant association between RASSF1A Ala133Ser polymorphism and lung cancer risk was found (Ser vs Ala: OR=2.27, 95% CI=1.29-4.02, Pheterogeneity=0.61; Ser/Ser+Ala/ Ser vs Ala/Ala: OR=2.42, 95% CI=1.33-4.42, P heterogeneity =0.75). In addition, in subgroup analyses by ethnicity, it was found that the RASSF1A Ala133Ser polymorphism was associated with overall cancer risk in Asians (Ser vs Ala: OR=1.37, 95% CI=1.06-1.77, P heterogeneity =0.06) and Caucasians (Ser/Ser+Ala/Ser vs Ala/Ala: OR=2.21, 95% CI=1.01-4.82, P heterogeneity ≤0.001). Conclusions: This meta-analysis suggests, for the first time, that RASSF1A Ala133Ser polymorphism may contribute to cancer susceptibility, especially for lung cancer. Besides, additional well-designed studies with larger sample size focusing on different ethnicities and cancer types are needed to confirm these findings.

show abstract

Apoptosis gene polymorphisms and risk of prostate cancer: A hospital-based study of German patients treated with brachytherapy

Cited by 26 publications

References 47 publications

Impact of Caspase-8 (CASP8) -652 6N Del and D302H Polymorphisms on Prostate Cancer in Different Ethnic Groups

Impact of Caspase-8 (CASP8) -652 6N Del and D302H Polymorphisms on Prostate Cancer in Different Ethnic Groups

Genetic Association Studies on Prostate Cancer

Association between RASSF1A Ala133Ser Polymorphism and Cancer Susceptibility: A Meta-Analysis Involving 8,892 Subjects

Contact Info

Product

Resources

About